ONC.L - Oncimmune Holdings Plc
Oncimmune Holdings Plc
MediCity
D6 Building 1 Thane Road
Nottingham NG90 6BH
United Kingdom
44 1157 840 500
https://www.oncimmune.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees:
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Dr. Adam Mark Hill Ph.D. | CEO & Director | 439k | N/A | 1980 |
| Mr. Matthew Hall | Chief Financial Officer | N/A | N/A | N/A |
| Prof. Tariq Sethi M.D., B.Sc., M.A., Ph.D., FRCP | Chief Scientific Officer | N/A | N/A | N/A |
| Ms. Cléa Rosenfeld | Head of Investor Relations | N/A | N/A | N/A |
| Mr. Ron Kirschner | Gen. Counsel & Company Sec. | N/A | N/A | N/A |
| Mr. Maarten Brusse | Chief Commercial Officer of Asia | N/A | N/A | N/A |
| Mr. Cameron Barnard | Chief Bus. Officer | N/A | N/A | N/A |
Description
Oncimmune Holdings plc develops and commercializes technologies that enable cancer diagnosis in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, a immunodiagnostic test for detecting and identifying lung cancer. The company also develops SeroTag, a platform that is used to discover and validate biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc has a collaboration with Siemens Healthineers AG. Oncimmune Holdings plc was incorporated in 2015 and is based in Nottingham, the United Kingdom.
Corporate governance
Oncimmune Holdings Plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.
